---
title: "Akeso doses first patient in Phase Ib/II NSCLC trial of HER3 ADC AK138D1 with ivonescimab"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293999468.md"
description: "Akeso has dosed the first patient in a Phase Ib/II trial evaluating its HER3 ADC AK138D1, either alone or combined with ivonescimab, for advanced non-small cell lung cancer (NSCLC). The study targets various NSCLC settings, including first-line and resistance cases. Early monotherapy data showed anti-tumor activity and favorable safety. Akeso aims to leverage synergy between the combination therapy and its IO-ADC strategy to improve patient outcomes."
datetime: "2026-07-28T02:36:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293999468.md)
  - [en](https://longbridge.com/en/news/293999468.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293999468.md)
generator: "portal-rs"
---

# Akeso doses first patient in Phase Ib/II NSCLC trial of HER3 ADC AK138D1 with ivonescimab

-   Akeso dosed the first patient in a Phase Ib/II study of its HER3 ADC AK138D1, alone or with ivonescimab, in advanced NSCLC. \* Early AK138D1 monotherapy results have already been presented from studies in China and Australia, showing anti-tumor activity with a favorable safety profile. \* The new trial targets first-line NSCLC, EGFR-TKI resistance, immuno-chemotherapy resistance, aiming to broaden use across major treatment settings. \* Akeso expects the AK138D1-ivonescimab combination to improve outcomes through synergy while maintaining tolerability, supporting its IO-ADC strategy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607272235PR\_NEWS\_USPR\_\_\_\_\_CN13511) on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Akeso says China NMPA clears Phase I trial for B7-H3 ADC AK157D1 in solid tumors](https://longbridge.com/en/news/296571352.md)
- [Akeso says Phase III ivonescimab-chemo trial in biliary tract cancer meets overall survival endpoint](https://longbridge.com/en/news/297257007.md)
- [AKESO  Ivonescimab Plus Chemotherapy Phase III Study Meets Primary Overall Survival Endpoint](https://longbridge.com/en/news/296969973.md)
- [China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial](https://longbridge.com/en/news/297148879.md)
- [Ivonescimab regimen shows OS superiority in Phase III HARMONi-GI1, Summit Therapeutics notes](https://longbridge.com/en/news/297053863.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**